Testing a new arthritis medication in children with joint inflammation

This trial is testing a new medication called bimekizumab in children ages 2 to under 18 who have active arthritis, specifically the types that affect joints and the places where tendons attach to bones. Researchers want to understand how the medication moves through the body and whether it is safe and helpful for these young patients. The medication is given as an injection under the skin, with doses adjusted based on each child's weight.

Children with these types of arthritis can experience significant joint pain and swelling that limits their activities. Current treatment options don't work well enough for all patients, so researchers are testing this new medication to see if it can better control the inflammation and help children feel better and stay more active.